Latest News Archive

Please select Category, Year, and then Month to display items
Years
2019 2020 2021 2024
Previous Archive
31 March 2020 | Story Leonie Bolleurs | Photo Supplied
UFS Covid-19 vaccine research team
Prof Robert Bragg and members of the Veterinary Biotechnology research group believe that finding a vaccine for COVID-19 will not be a ‘quick fix’. From the left are: Prof Bragg, Samantha McCarlie, Liese Kilian, and Dr Charlotte Boucher-van Jaarsveld. The photo was taken during the World Veterinary Poultry Association congress in Thailand in 2019.

On 31 March 2020, there were 804 061 coronavirus cases and 39 064 deaths globally due to the outbreak. According to media reports, there is still no licensed vaccine for COVID-2019 – the cause of our current global health emergency.  

Prof Robert Bragg, researcher at the University of the Free State (UFS), says this is without a doubt the most pressing research need in the world today. 

The Veterinary Biotechnology research group in the Department of Microbial, Biochemical, and Food Biotechnology at the UFS recently submitted an article for publication on the design of a possible COVID-19 vaccine, based on work they have done on infectious bronchitis virus (also a coronavirus). The article, authored by the group of which Prof Bragg is a member, is titled: A sub-unit vaccine produced in 'Yarrowia lipolytica' against COVID-19: Lessons learnt from infectious bronchitis virus. 

The research group, consisting of researchers and postgraduate students, is mostly looking at strategies for improved disease control, mainly in avian species, through vaccine development, treatment, and biosecurity.

Prof Bragg says their main aim with this study was to get the research out there so that the bigger pharmaceutical companies could take up the design of a possible COVID-19 vaccine and assist with the development of a vaccine. 

He says the research group’s role in this lengthy process would be to express the protein, which could be used in the development of a possible vaccine. “Thereafter, it will have to be taken up by a vaccine manufacturer to get the vaccine made and to the market.”

Developing a vaccine
Liese Kilian, a member of the research group, finished writing up her MSc thesis in Microbiology in the UFS Department of Microbial, Biochemical, and Food Biotechnology in December 2019 – the same time that COVID-19 originated in China. She has been working on the development of an edible sub-unit vaccine against the infectious bronchitis virus (IBV), which is a widespread avian coronavirus. This virus is specific to poultry and is different from COVID-19. 

Kilian’s project was conducted under the supervision of Prof Bragg and Dr Charlotte Boucher-van Jaarsveld. Dr Boucher-van Jaarsveld is a research fellow in the university’s Department of Microbial, Biochemical and Food Biotechnology.

Kilian, with the assistance of Samantha Mc Carlie, currently a master’s student in the research group, substituted the genetic code of the IBV with the genetic code of the COVID-19 virus, which were already published at that stage. Thus, a gene for the development of a possible sub-unit vaccine against the S1 spike protein of COVID-19 was developed for expression in the same yeast strain used to express the spike protein of IBV. A sub-unit vaccine can be described as part of a pathogen, triggering an immune response against the pathogen from which it is derived.

After Killian successfully developed the gene for this study, she expressed the S1 spike protein of the IBV in a yeast-based expression system developed by the research group. Dr Boucher-van Jaarsveld says this simply means that the yeast takes up the foreign genetic material (viral gene) into its own genetic make-up and makes more of this protein as if it is part of the yeast’s normal material. 

“The images of COVID-19 are being shown constantly in the media and the ‘spikes’ can be seen on all of these images. These spikes are very typical for all coronaviruses and there is some level of similarity between the structure of these spikes in many of the coronaviruses,” Prof Bragg adds.

According to the World Health Organisation, the spike protein is a promising candidate for a sub-unit vaccine due to its immunogenicity and safety, as well as manufacturing and stability considerations during large-scale development.

Prof Bragg says there are many different expression systems that are widely used. Producing the sub-unit vaccine in a yeast species is beneficial for the work they are doing. A yeast expression system is favourable as large-scale production, is less expensive compared to mammalian cell lines, and can be applied as an edible vaccine.

“The technology to grow massive volumes of yeast are also very well established. This, after all, is how beer is made!” Prof Bragg says. Dr Boucher-van Jaarsveld adds: “The expression of an antigen is not necessarily just geared towards vaccines but can also be used in the development of diagnostic tests to screen populations for infections.”

Working with other researchers
“Now that the situation is all but out of control, we maybe need to investigate the possibilities of working with other key researchers at the UFS as well as other universities in South Africa to develop the vaccine or diagnostic reagents locally. Discussions on this aspect are already underway.”

Several other universities in South Africa are also working to find a cure for the virus. Government availed funding for more research on the matter. According to Higher Education, Science and Technology Minister, Blade Nzimande, the University of Cape Town, the Council for Scientific and Industrial Research, as well as the Vaccines Institute of Southern Africa are working on the development of a vaccine.

Prof Bragg expressed the hope of obtaining funding for this work. “Because without funding, we will not be able to do anything with this data,” he says. They are currently investigating different funding options. 

“The sooner we start on the development of a vaccine, the sooner there will be one, but it will not be a ‘quick fix’. It must be stressed that, even if vaccine development is fast-tracked through the regulatory bodies, it will take many months (if not years) to move from the laboratory to the first human experimentation. It will take even longer before any human vaccine can be rolled out,” says Prof Bragg.



News Archive

Number of NRF-rated researchers increases in 2012
2012-10-29

29 October 2012

Three researchers at the University of the Free State received B-ratings for 2013 from the National Research Foundation (NRF). Prof. Johan Henning, Dean of Law, obtained the highest rating in his field of mercantile law in South Africa, a B1.

Prof. Jackie Naudé from Classical and Near Eastern Studies and Prof. Dingie Janse van Rensburg, Professor Extraordinary at the Centre for Health Systems Research and Development, also obtained B3-ratings. Prof. Naudé is the first B-rated researcher in the Faculty of Humanities.
Prof. Helene Strauss obtained the highest rating (Y1) for a UFS young scholar in the Humanities.
In total, the NRF rated researchers at the UFS grew from 95 in 2011 to 109 in 2012, a growth of almost 15 percent.
The NRF ratings committee consist of three reviewers from South Africa and three from abroad. A rating is valid for six years and researchers must reapply for rating before the end of that period.
For a B1-rating all reviewers must be firmly convinced that the applicant enjoys considerable international recognition for the high quality of the researcher’s recent output, with some indicating that the researcher is a leading international scholar in a field. For a B3-rating most of the reviewers must be convinced that the researcher enjoys international recognition for the high quality and impact of the research.
Prof. Jonathan Jansen, Vice-Chancellor and Rector, said in the UFS Research Report “The UFS now has among the highest number of NRF-rated scientists per size of the academic faculty and we have seen the productivity graph bear witness to a record growth in our funded research outputs; we have won our first-ever NRF/DST Research Chairs. In each of these achievements, the excellence we seek comes with and through the diversity we celebrate.”
More ratings and renewals were expected by the time of Bult went to print.. More than 35 researchers applied for ratings or renewal of ratings.
  • Colleagues who were admitted to the prestigious Academy of Science of South Africa (ASSAf) are Profs. Pumla Gobodo-Madikizela, Driekie Hay, Heidi Hudson, Lodewyk Kock, Odireleng Ntwaeaborwa, Hugh Patterton, Ian Phimister and Melanie Walker. ASSAf was established in 1996 with the mission of using science for the benefit of society. New members are elected after nomination by four existing members (at least two of whom do so from personal knowledge of the candidate). ASSAf has some 350 members and represents South Africa in the international community of science academies.
  • Dr Marieka Gryzenhout of Plant Sciences became a member of South African Young Academy of Science (SAYAS). SAYAS celebrated its first year in 2012. It was launched as a means to enable South Africa’s young scientists to fully participate in locally and internationally relevant research and development agendas. Prof. Aldo Stroebel, Director: Internationalisation, is also a member of SAYAS.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept